Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezvilutamide + ADT + docetaxel vs rezvilutamide + ADT in high-volume mHSPC with suboptimal PSA response
ChiCTR2400086493Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of rezvilutamide in prostate cancer (PCa) (2 arms), sponsored by Tianjin Medical University. Primary endpoint: Radiographic progression-free survival (rPFS). Planned start Jul 2024; status: not yet recruiting.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2400086493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086493.